Craft

AlloVir

Stock Price

$0.8

2024-04-12

Market Capitalization

$88.1 M

2024-04-12

AlloVir Summary

Company Summary

Overview
AlloVir (formerly known as ViraCyte) is a company that develops and delivers transformative cell therapies for patients suffering from life-threatening virus-associated diseases. It focuses on the clinical development of novel cell therapies designed to restore natural T-cell immunity against devastating virus-associated diseases in immunocompromised patients, including stem cell and organ transplant recipients.
Type
Public
Status
Active
Founded
2013
HQ
Waltham, MA, US | view all locations
Website
https://www.allovir.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Ann Leen

    Ann Leen, Chief Scientific Officer

  • Edward Miller
  • Jeroen van Beek

    Jeroen van Beek, Chief Commercial Officer

  • Vikas Sinha

    Vikas Sinha, President and Chief Financial Officer, Director

Operating MetricsView all

Patents (US)

2

Jul, 2020

Patents (Foreign)

30

Jul, 2020

Patents Pending

19

Jul, 2020

LocationsView all

4 locations detected

  • Waltham, MA HQ

    United States

    1100 Winter St

  • Houston, TX

    United States

    2925 Richmond Ave. Suite 1200

  • Waltham, MA

    United States

    200 Smith St #301

  • Milan, Lombardia

    Italy

    Via Melchiorre Gioia, 8

AlloVir Financials

Summary Financials

Net income (FY, 2023)
($190.4M)
Cash (FY, 2023)
$90.1M
EBIT (FY, 2023)
($199.9M)
Enterprise value
$25.4M

Footer menu